Akbuğa J., Ozbaş-Turan S. and Erdoğan N. (2004) Plasmid-DNA loaded chitosan microspheres for in vitro IL-2 expression. European journal of pharmaceutics and biopharmaceutics 58(3):501-507.
Ascierto M.L., Kmieciak M., Idowu M.O., Manjili R., Zhao Y., Grimes M. et. al. (2012) A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast cancer research and treatment 131(3):871-880.
Bogdanova N., Helbig S. and Dörk T. (2013) Hereditary breast cancer: ever more pieces to the polygenic puzzle. Hereditary cancer in clinical practice 11(1):1-16.
Burstein H.J. and Griggs J.J. (2010) Adjuvant hormonal therapy for early-stage breast cancer. Surgical oncology clinics of North America 19:639-647.
Cai J.,Guan H., Fang L.,Yang Y., Zhu X., Yuan J., et al. (2013) MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis. The Journal of clinical investigation 123(2):566-579.
Cheng X.,Chen J. and Huang Z. (2018) miR-372 promotes breast cancer cell proliferation by directly targeting LATS2. Experimental and therapeutic medicine 15(3):2812-2817.
Dunnwald L.K., Rossing M.A. and Li CI. (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast cancer research 9(1):1-10.
Elieh-Ali-Komi, D. and Hamblin M.R. (2016) Chitin and Chitosan: Production and Application of Versatile Biomedical Nanomaterials. International Journal of Advanced Research 4(3):411-427.
Friedman A.E. (2007) Can a single model explain both breast cancer and prostate cancer? Theoretical biology & medical modelling 4(28):28.1-13.
Iorio M.V., Ferracin M., Liu C-G.,Veronese A., Spizzo R., Sabbioni S., et al. (2005) MicroRNA gene xpression deregulation in human breast cancer. Cancer Resarch 65(16):7065-7070.
Krell J., Frampton A.E., Jacob J., Pellegrino L., Roca-Alonso L., Zeloof D., et al. (2012) The clinico-pathologic role of microRNAs miR-9 and miR-151-5p in breast cancer metastasis. Molecular diagnosis & therapy 16(3):167-172.
Majeed W., Aslam B., Javed I., Khaliq T., Muhammad F., Ali A. et al. (2014) Breast cancer: major risk factors and recent developments in treatment. Asian Pacific Journal of Cancer Prevention 15(8):3353-3358.
Osborne C., Wilson P. and Tripathy D. (2004) Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. The oncologist 9(4):361-377.
Özbaş-Turan S. and Akbuğa J. (2011) Plasmid DNA-loaded chitosan/TPP nanoparticles for topical gene delivery. Drug delivery 18(3):215-222.
Paliwal S.R., Paliwal R., Pal H.C., Saxena A.K., Sharma P.R., Gupta P.N., et al. (2012) Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy. Molecular pharmaceutics 9(1):176-186.
Regan M.M., Neven P., Giobbie-Hurder A., Goldhirsch A., Ejlertsen B., Mauriac L., et al. (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. The Lancet. Oncology 12(12):1101-1108.
Sharma G.N., Dave R., Sanadya J., Sharma P. and Sharma K. (2010) Various types and management of breast cancer: an overview. Journal of advanced pharmaceutical technology & research 1(2):109-126.
Soliman H. (2013) Immunotherapy Strategies in the Treatment of Breast Cancer. Cancer Control 20(1):17-21.
Velpurisiva P., Gad A., Piel B., Jadia R. and Rai P. (2017) Nanoparticle Design Strategies for Effective Cancer Immunotherapy. Journal of biomedicine 2(2):64-77.
Zhang T., Hu Y., Ju J., Hou L., Li Z., Xiao D., et al. (2016) Downregulation of miR-522 suppresses proliferation and metastasis of non-small cell lung cancer cells by directly targeting DENN/MADD domain containing 2D. Scientific reports 6:1-12.
Zhao Y.X., Liu H.C., Ying W.Y., Wang C.Y., Yu Y.J., Sun W.J., et al. (2017) microRNA-372 inhibits proliferation and induces apoptosis in human breast cancer cells by directly targeting E2F1. Molecular medicine reports 16(6):8069-8075.
